CONTI, ALESSANDRO
 Distribuzione geografica
Continente #
NA - Nord America 2.879
EU - Europa 1.384
AS - Asia 1.091
SA - Sud America 239
Continente sconosciuto - Info sul continente non disponibili 83
AF - Africa 80
OC - Oceania 1
Totale 5.757
Nazione #
US - Stati Uniti d'America 2.835
SG - Singapore 347
IT - Italia 242
CN - Cina 226
RU - Federazione Russa 208
UA - Ucraina 203
VN - Vietnam 199
BR - Brasile 191
DE - Germania 154
SE - Svezia 153
IE - Irlanda 110
TR - Turchia 94
FR - Francia 74
DK - Danimarca 72
FI - Finlandia 59
GB - Regno Unito 52
CI - Costa d'Avorio 50
HK - Hong Kong 49
IN - India 40
KR - Corea 39
BD - Bangladesh 25
CA - Canada 20
AR - Argentina 17
MX - Messico 16
NL - Olanda 14
ZA - Sudafrica 13
PL - Polonia 12
IQ - Iraq 11
EC - Ecuador 9
CO - Colombia 8
ES - Italia 8
ID - Indonesia 8
JP - Giappone 8
MA - Marocco 7
PH - Filippine 6
BE - Belgio 5
EU - Europa 5
MY - Malesia 5
SA - Arabia Saudita 5
VE - Venezuela 5
AT - Austria 4
EG - Egitto 4
LT - Lituania 4
JO - Giordania 3
LB - Libano 3
PK - Pakistan 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BO - Bolivia 2
BY - Bielorussia 2
CL - Cile 2
IL - Israele 2
LY - Libia 2
PE - Perù 2
PS - Palestinian Territory 2
RS - Serbia 2
TH - Thailandia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KI - Kiribati 1
KW - Kuwait 1
NG - Nigeria 1
NI - Nicaragua 1
PR - Porto Rico 1
PY - Paraguay 1
QA - Qatar 1
RO - Romania 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 5.679
Città #
Ashburn 458
Chandler 221
Jacksonville 212
Singapore 201
Fairfield 176
San Jose 149
New York 113
Dublin 110
Council Bluffs 101
Wilmington 101
Boardman 90
Dallas 90
Seattle 84
Woodbridge 84
Beijing 80
Ho Chi Minh City 70
Abidjan 50
The Dalles 49
Hong Kong 48
Houston 48
Cambridge 44
Lawrence 43
Princeton 43
San Mateo 43
Lauterbourg 41
Hanoi 38
Los Angeles 37
Munich 37
Centro 36
Moscow 34
Ann Arbor 31
San Diego 21
Santa Clara 20
Chicago 18
London 16
Milan 16
São Paulo 16
Da Nang 15
Hefei 15
Turku 15
Orem 14
Turin 14
Brooklyn 12
Chennai 12
Helsinki 11
Warsaw 11
Guangzhou 10
Buffalo 9
Johannesburg 9
Pune 9
Rome 9
Des Moines 8
Marche 8
Phoenix 8
Rio de Janeiro 8
Tokyo 8
Frankfurt am Main 7
Naples 7
Porto Alegre 7
Redmond 7
Shanghai 7
Stockholm 7
Atlanta 6
Haiphong 6
Manchester 6
Montegiorgio 6
Montreal 6
Poplar 6
Toronto 6
Wuxi 6
Ancona 5
Brussels 5
Cupra Marittima 5
Hải Dương 5
Norwalk 5
Porto 5
Quận Ba 5
San Francisco 5
Thái Nguyên 5
Washington 5
Baghdad 4
Belo Horizonte 4
Boston 4
Brasília 4
Curitiba 4
Jiaxing 4
Mexico City 4
Mumbai 4
Nuremberg 4
Palermo 4
Amsterdam 3
Ankara 3
Biên Hòa 3
Cairo 3
Cape Town 3
Charlotte 3
Chiswick 3
City of London 3
Columbus 3
Guarulhos 3
Totale 3.484
Nome #
Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy 202
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 202
Emerging biomarkers in bladder cancer identified by network analysis of transcriptomic data 194
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 191
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 172
Prostatic fiducial markers implantation by transrectal ultrasound for adaptive image guided radiotherapy in localized cancer: 7-years experience 169
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 165
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 165
Sphincter: properties, types and application 163
Perivascular epithelioid cell tumor (PEC-ome) of the prostate: ultrasound feature in case report 159
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 158
Metabolic Alterations in Renal and Prostate Cancer 157
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies 157
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 153
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 142
PEC-OME of the prostate: case report 141
Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma 141
Present and future of personalized medicine in adult genitourinary tumors 136
NEPHRON-SPARING SURGERY FOR RENAL MASSES >4 CM (CT1B-T2) IN PATIENTS WITH CHRONIC RENAL FAILURE 136
Biomarkers for VEGF-targeted therapy in renal cell carcinoma: an UpTo Date 135
Diagnostic-therapeutic pathway for small lesions of the testis 135
Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives. 131
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies 130
New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials 130
Repeated injection of botulinum toxin a in patients with neurogenic bladder: our experience. 129
Urinary catheters and biofilm formation 123
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma 121
Role of STAT3 pathway in genitourinary tumors 116
Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients 115
Efficacy and safety of alfa-1-blockers for the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a prospective study 114
Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: A systematic review and meta-analysis 114
Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors 111
The route to personalized medicine in bladder cancer: where do we stand? 111
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy 109
α1-Blockers for the treatment of recurrent urinary tract infections in women with dysfunctional voiding: A prospective randomized study. 107
Recurrent urinary tract infections and dysfunctional voiding 104
Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis 96
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma 94
Survival in Patients with Clear Cell Renal Cell Carcinoma is Predicted by HIF-1α Expression 93
VEGF and HIF in renal cell carcinogenesis. 90
RESULTS OF NEPHRON-SPARING SURGERY WITHOUT VASCULAR CLAMPING IN PATIENTS WITH CHRONIC RENAL FAILURE 86
Re: Gut Microbiome Influences Efficacy of PD-1-based Immunotherapy Against Epithelial Tumors 86
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma 74
Totale 5.757
Categoria #
all - tutte 27.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.409


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022205 0 0 0 9 2 26 5 15 24 28 24 72
2022/2023636 58 94 44 48 48 53 3 40 168 8 48 24
2023/2024419 75 7 28 47 56 131 8 12 3 9 1 42
2024/2025710 101 53 11 10 54 22 62 21 145 43 87 101
2025/20261.944 169 141 80 182 256 144 317 214 166 128 59 88
2026/2027262 83 72 92 15 0 0 0 0 0 0 0 0
Totale 5.757